U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H41NO4
Molecular Weight 467.6401
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUPRENORPHINE

SMILES

[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]57CC[C@@]2(OC)[C@]([H])(C7)[C@](C)(O)C(C)(C)C)=CC=C3O

InChI

InChIKey=RMRJXGBAOAMLHD-IHFGGWKQSA-N
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

HIDE SMILES / InChI

Description

Buprenorphine is an opioid analgesic, used to treat opioid addiction, moderate acute pain, and moderate chronic pain. Buprenorphine is a partial agonist at the mµ-opioid receptor and an antagonist at the kappa-opioid receptor. One unusual property of buprenorphine observed in vitro studies is its very slow rate of dissociation from its receptor. This could account for its longer duration of action than morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. The principal action of the therapeutic value of buprenorphine is analgesia and is thought to be due to buprenorphine binding with high affinity to opioid receptors on neurons in the brain and spinal cord. Buprenorphine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Buprenorphine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Buprenorphine produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

CNS Activity

Originator

Approval Year

1981
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
290
 1.5 nM [Ki]
Antagonist
2778
 2.5 nM [Ki]
Antagonist
2778
 6.1 nM [Ki]
Nociceptin receptor
14
Target ID: P41146
Gene ID: 4987.0
Gene Symbol: OPRL1
Target Organism: Homo sapiens (Human)
Partial Agonist
290
 77.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
BUTRANS

Approved Use

SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1)

Launch Date

2010
Primary
Approved
8429
BUTRANS

Approved Use

SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1)

Launch Date

2010
Primary
Phase IV
63
BUTRANS

Approved Use

SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1)

Launch Date

2010
Primary
Phase IV
63
BUTRANS

Approved Use

SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1)

Launch Date

2010
Primary
Phase IV
63
BUTRANS

Approved Use

SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1)

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.17 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf
75 μg single, oral
dose: 75 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUPRENORPHINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.63 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf
75 μg single, oral
dose: 75 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUPRENORPHINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf
75 μg single, oral
dose: 75 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUPRENORPHINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf
75 μg single, oral
dose: 75 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUPRENORPHINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5.714 ug/kg 1 times / day single, intravenous
Studied dose
Dose: 5.714 ug/kg, 1 times / day
Route: intravenous
Route: single
Dose: 5.714 ug/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/16547090/
healthy, 22 to 35 years
n = 5
Health Status: healthy
Age Group: 22 to 35 years
Sex: M
Population Size: 5
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/16547090/
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/16547090/
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (4.4%)
Vomiting (1.6%)
Constipation (0.8%)
Dizziness (1.4%)
Headache (1.1%)
Somnolence (1.1%)
Fatigue (0.8%)
QT interval prolonged (0.5%)
Anxiety (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
32 mg 1 times / day single, oral
Highest studied dose
Dose: 32 mg, 1 times / day
Route: oral
Route: single
Dose: 32 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8181201/
healthy, mean age 32.3 years
n = 4
Health Status: healthy
Age Group: mean age 32.3 years
Sex: M
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/8181201/
Sources:
https://pubmed.ncbi.nlm.nih.gov/8181201/
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (below serious, 36 patients)
Vomiting (below serious, 24 patients)
Constipation (below serious, 9 patients)
Dizziness (below serious, 18 patients)
Headache (below serious, 15 patients)
Somnolence (below serious, 6 patients)
Pruritus (below serious, 2 patients)
Hyperhidrosis (below serious, 2 patients)
Oxygen saturation decreased (below serious, 6 patients)
Hot flush (below serious, 2 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (below serious, 47 patients)
Vomiting (below serious, 33 patients)
Constipation (below serious, 6 patients)
Dizziness (below serious, 26 patients)
Headache (below serious, 23 patients)
Somnolence (below serious, 6 patients)
Pruritus (below serious, 2 patients)
Hyperhidrosis (below serious, 1 patient)
Oxygen saturation decreased (below serious, 8 patients)
Hot flush (below serious, 2 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Other AEs: Angioedema, Nausea...
Other AEs:
Angioedema (serious, 1 patient)
Nausea (below serious, 68 patients)
Vomiting (below serious, 59 patients)
Constipation (below serious, 8 patients)
Dizziness (below serious, 44 patients)
Headache (below serious, 13 patients)
Somnolence (below serious, 11 patient)
Pruritus (below serious, 11 patient)
Hyperhidrosis (below serious, 8 patients)
Oxygen saturation decreased (below serious, 7 patients)
Dehydration (below serious, 7 patients)
Hot flush (below serious, 5 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
AEs

AEs

AESignificanceDosePopulation
Respiratory depression
5.714 ug/kg 1 times / day single, intravenous
Studied dose
Dose: 5.714 ug/kg, 1 times / day
Route: intravenous
Route: single
Dose: 5.714 ug/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/16547090/
healthy, 22 to 35 years
n = 5
Health Status: healthy
Age Group: 22 to 35 years
Sex: M
Population Size: 5
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/16547090/
Anxiety 0.5%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
QT interval prolonged 0.5%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Constipation 0.8%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Fatigue 0.8%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Headache 1.1%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Somnolence 1.1%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Dizziness 1.4%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Vomiting 1.6%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Nausea 4.4%
Disc. AE
480 ug 2 times / day multiple, oral (mean)
Recommended
Dose: 480 ug, 2 times / day
Route: oral
Route: multiple
Dose: 480 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
unhealthy, adult
n = 2127
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 2127
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf
Page: nda/2015/207932Orig1s000MedR.pdf - p.53
Headache below serious, 15 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Dizziness below serious, 18 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hot flush below serious, 2 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hyperhidrosis below serious, 2 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Pruritus below serious, 2 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Vomiting below serious, 24 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Nausea below serious, 36 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Oxygen saturation decreased below serious, 6 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Somnolence below serious, 6 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Constipation below serious, 9 patients
0.125 mg 3 times / day multiple, sublingual
Dose: 0.125 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.125 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 82
Health Status: unhealthy
Condition: postoperative pain
Population Size: 82
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hyperhidrosis below serious, 1 patient
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hot flush below serious, 2 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Pruritus below serious, 2 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Headache below serious, 23 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Dizziness below serious, 26 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Vomiting below serious, 33 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Nausea below serious, 47 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Constipation below serious, 6 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Somnolence below serious, 6 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Oxygen saturation decreased below serious, 8 patients
0.25 mg 3 times / day multiple, sublingual
Dose: 0.25 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.25 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 80
Health Status: unhealthy
Condition: postoperative pain
Population Size: 80
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Pruritus below serious, 11 patient
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Somnolence below serious, 11 patient
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Headache below serious, 13 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Dizziness below serious, 44 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hot flush below serious, 5 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Vomiting below serious, 59 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Nausea below serious, 68 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Dehydration below serious, 7 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Oxygen saturation decreased below serious, 7 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Constipation below serious, 8 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Hyperhidrosis below serious, 8 patients
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Angioedema serious, 1 patient
0.5 mg 3 times / day multiple, sublingual
Dose: 0.5 mg, 3 times / day
Route: sublingual
Route: multiple
Dose: 0.5 mg, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
unhealthy
n = 81
Health Status: unhealthy
Condition: postoperative pain
Population Size: 81
Sources:
https://clinicaltrials.gov/ct2/show/NCT02634788
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587
substrate
1037
substrate
1217

inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Nav1.7
36

Cav1.2
45

Nav1.5
97

P-gp
1461

BCRP
699

CYP1A
72

CYP2B6
810

CYP2C19
1478

CYP2C8/9
44

CYP2E1
882
P-gp
1537

CYP1A1
349

CYP1A2
1054

CYP2A6
543

CYP2B6
664

CYP2C8
693

CYP2C18
138

CYP2C19
991

CYP2E1
667

CYP3A5
395

CYP3A7
110

UGT1A1
418

UGT1A3
422

UGT1A4
347

UGT1A6
307

UGT1A9
380

UGT2B7
389

UGT2B17
213
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1925
 strong [Ki 14.7 uM]
CYP2D6
1891
 strong [Ki 21.4 uM]
CYP1A
121
 weak [Ki 132 uM]
CYP2B6
1001
 weak [Ki 133 uM]
CYP2C19
1553
 weak [Ki 146 uM]
CYP2C8/9
44
 weak [Ki >300 uM]
CYP2E1
970
 weak [Ki >300 uM]
Nav1.7
36
 yes [IC50 47 uM]
BCRP
773
 yes
P-gp
1650
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
349
 no
CYP1A2
1054
 no
CYP2A6
543
 no
CYP2B6
664
 no
CYP2C18
138
 no
CYP2C19
991
 no
CYP2C9
1037
 no
CYP2E1
667
 no
P-gp
1537
 no
UGT1A4
347
 no
UGT1A6
307
 no
UGT1A9
380
 no
CYP2C8
693
 yes
CYP2D6
1217
 yes
CYP3A4
1737
 yes
CYP3A5
395
 yes
CYP3A7
110
 yes
UGT1A1
418
 yes
UGT1A3
422
 yes
UGT2B17
213
 yes
UGT2B7
389
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Cav1.2
49
Nav1.5
100
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3216
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3216
ZINC
ZINC000001319780
http://zinc15.docking.org/substances/ZINC000001319780
PubMed

PubMed

TitleDatePubMed
Disulfiram and buprenorphine for treating cocaine addiction.
2000 Jul
Relationship between cocaine-induced hepatotoxic neurobehavioral & biochemical changes in mice: the antidotal effects of buprenorphine.
2000 May 26
Opioid antagonists for smoking cessation.
2001
Treatment of opioid addiction in physicians' offices: it's about time.
2001
[Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments].
2001 Apr
Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry.
2001 Apr 25
Rapid heroin detoxification using a single high dose of buprenorphine.
2001 Apr-Jun
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia combined with continuous epidural anesthesia].
2001 Aug
[The benefit of combining spinal morphine and intravenous buprenorphine for perioperative pain].
2001 Aug
Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor.
2001 Aug
Office-based treatment for opioid dependence: reaching new patient populations.
2001 Aug
Effect of perinatal buprenorphine exposure on development in the rat.
2001 Aug
Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.
2001 Feb
Hepatitis after intravenous buprenorphine misuse in heroin addicts.
2001 Feb
Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation.
2001 Feb
Response variability to analgesics: a role for non-specific activation of endogenous opioids.
2001 Feb 15
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia].
2001 Jan
Opioid chronopharmacology.
2001 Jul
[The effect of intravenous patient controlled analgesia on activities of daily life and medical expense after thoracotomy].
2001 Jul
Influence of buprenorphine analgesia on post-operative recovery in two strains of rats.
2001 Jul
The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine.
2001 Jul
Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys.
2001 Jul
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
2001 Jul 1
Buprenorphine added to the local anesthetic for brachial plexus block to provide postoperative analgesia in outpatients.
2001 Jul-Aug
An exploratory study of buprenorphine use in Bangladesh: a note.
2001 Jun
Epidural analgesia with a combination of bupivacaine and buprenorphine in rats.
2001 Jun
Three-choice discrimination in pigeons is based on relative efficacy differences among opioids.
2001 Jun
Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.
2001 Jun
Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy.
2001 Jun
Electrically-assisted transdermal delivery of buprenorphine.
2001 Jun 15
SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report.
2001 Mar
Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma.
2001 Mar
[Anesthetic management of two patients with essential thrombocythemia].
2001 May
Comment on Valenciano et al's "Unsafe injecting practices among attendees of syringe exchange programmes in France".
2001 May
Antinociceptive activity of and clinical experience with buprenorphine in swine.
2001 May
[Review of scientific evidence on alternatives to methadone in the psychopharmacologic treatment of opiate dependence].
2001 May-Jun
Comparison of methadone and high dosage buprenorphine users in French care centres.
2001 Oct
Preoperative blood pressure and intraoperative hypothermia during lower abdominal surgery.
2001 Sep
Effects of medetomidine and buprenorphine administered for sedation in dogs.
2001 Sep
HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
2001 Sep
[Buprenorphine in pregnancy].
2001 Sep
Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.
2001 Sep 1
Deaths involving buprenorphine: a compendium of French cases.
2001 Sep 15
Patents

Patents

JP2003515526A
462
JP2004534002A
17
JP2004536811A
36
JP2009242415A
4
JP2013543488A
4
JP4790219B2
12
JPH03163014A
4

Sample Use Guides

In Vivo Use Guide
The initial starting dose is 1 mL buprenorphine hydrochloride injection (0.3 mg buprenorphine) given by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed. Repeat once (up to 0.3 mg) if required, 30 to 60 minutes after initial dosage, giving consideration to previous dose pharmacokinetics, and thereafter only as needed. In high-risk patients (e.g., elderly, debilitated, presence of respiratory disease, etc.) and/or in patients where other CNS depressants are present, such as in the immediate postoperative period, the dose should be limited to the minimum required. Buprenorphine hydrochloride has been used in pediatric patients 2 to 12 years of age at doses between 2 to 6 micrograms/kg of body weight given every 4 to 6 hours. There is insufficient experience to recommend a dose in infants below the age of two years, single doses greater than 6 micrograms/kg of body weight, or the use of a repeat or second dose at 30 to 60 minutes (such as is used in adults).
Route of Administration: Other
In Vitro Use Guide
Functional activity of μ receptors in intact cells was determined by measuring receptor-induced membrane potential change, which can be directly read by Molecular Devices Membrane Potential Assay Kit (Blue Dye) using the FlexStation 3® microplate reader. CHO cells transfected with human μ-opioid receptors were seeded in a 96-well plate (30 000 cells per well) 1 day prior to the experiments. For agonist assays, after brief washing, the cells were loaded with 225 μL of HBSS assay buffer (HBSS with 20 mM of HEPES, pH 7.4), containing the blue dye, and incubated at 37°C. After 30 min, 25 μL of the Buprenorphine were automatically dispensed into the wells by the FlexStation and receptor stimulation-mediated membrane potential change is recorded every 3 s for 60 s by reading 550–565 nm fluorescence excited at 530 nm wavelength.
Name Type Language
BUPRENORPHINE
EMA EPAR   EP   INN   JAN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
SUBLOCADE
Brand Name English
BUPRENORPHINE [JAN]
Common Name English
BUPRENORPHINE [EMA EPAR]
Common Name English
SUBOXONE
Brand Name English
Buprenorphine [WHO-DD]
Common Name English
BUPRENORPHINE [VANDF]
Common Name English
BUPRENORPHINE [ORANGE BOOK]
Common Name English
BUPRENORPHINE [EP MONOGRAPH]
Common Name English
buprenorphine [INN]
Common Name English
BUPRENORPHIN
Common Name English
BUPRENORPHINE [MI]
Common Name English
BUPRENORPHINE [MART.]
Common Name English
BUTRANS
Brand Name English
PROBUPHINE
Brand Name English
BRIXADI
Brand Name English
BUPRENORPHINE [EP IMPURITY]
Common Name English
ALKS-5461 COMPONENT BUPRENORPHINE
Code English
TEMGESIC
Brand Name English
Classification Tree Code System Code
WHO-VATC QN07BC51
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
NDF-RT N0000175685
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
WHO-ATC N07BC01
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
LIVERTOX NBK548871
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
NDF-RT N0000175689
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
DEA NO. 9064
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
NCI_THESAURUS C1506
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
WHO-ATC N02AE01
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
FDA ORPHAN DRUG 79093
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
EMA ASSESSMENT REPORTS SUBOXONE (AUTHORIZED: OPIOID-RELATED DISEASES)
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
WHO-ATC N07BC51
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
WHO-VATC QN07BC01
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
WHO-VATC QN02AE01
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
FDA ORPHAN DRUG 541116
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
Code System Code Type Description
PUBCHEM
644073
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
IUPHAR
1670
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL511142
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
ECHA (EC/EINECS)
257-950-6
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
NCI_THESAURUS
C61656
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
RXCUI
1819
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY RxNorm
MESH
D002047
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
MERCK INDEX
m2771
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY Merck Index
INN
3403
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
WIKIPEDIA
BUPRENORPHINE
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
FDA UNII
40D3SCR4GZ
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
DRUG CENTRAL
434
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
LACTMED
Buprenorphine
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
DAILYMED
40D3SCR4GZ
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
CAS
52485-79-7
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
EVMPD
SUB05985MIG
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
CHEBI
3216
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID2022705
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
SMS_ID
100000085263
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
DRUG BANK
DB00921
Created by admin on Fri Dec 15 15:13:47 GMT 2023 , Edited by admin on Fri Dec 15 15:13:47 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of BUPRENORPHINE
METABOLITE ACTIVE (PARENT)
Structure of BUPRENORPHINE 3-GLUCURONIDE
METABOLITE ACTIVE (PARENT)
Structure of NORBUPRENORPHINE
SALT/SOLVATE (PARENT)
Structure of BUPRENORPHINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966